THERATARGET

Basic Information

615 Arapeen Drive, Suite 302-Y
Salt Lake City, UT, 84108-1289

Company Profile

n/a

Additional Details

Field Value
DUNS: 828787379
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): This Phase I proposal addresses the significant need for improved treatment options for patients with liver cancer, the fifth highest incidence of cance in the wo ...

    STTR Phase I 2012 Department of Health and Human Services
  2. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    Amount: $148,304.00

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of targeted, backbone degradable, long-circulating polymer ...

    STTR Phase I 2011 Department of Health and Human Services
  3. Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of a polymeric delivery system that will deliver two antic ...

    STTR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government